Chemotherapy with Taxotere (docetaxel) might not be considered because the side effects are misunderstood. Individual experiences and side effects differ widely from one man to another. n Generally, chemotherapy is not as toxic as we think. Even if a patient feels that his chemotherapy is causing more grief than relief, it can be discontinued; there [...]
According to researchers at the H. Lee Moffitt Cancer Center & Research Institute, men with a mutation in their VAC14 gene are more susceptible to Docetaxil chemotherapy induced neuropathy and nerve pain. This debilitating side effect results from damage to the peripheral nerves and is felt by the man as weakness, numbness and pain most [...]
Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]
The PSA flare phenomenon when first starting chemotherapy with docetaxel has been noted by many clinicians. To evaluate this flare in men with castrate resistant prostate cancer treated with docetaxel, researchers retrospectively evaluated the charts of 56 men who received docetaxel-based chemotherapy in three different centers from August 1999 to August 2007. They found that [...]
Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed [...]